Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer

被引：0
|
作者：
Trarbach, T. [1 ,2 ]
Schuette, K. [1 ,2 ]
Stoehlmacher, J. [1 ,2 ]
Goekkurt, E. [1 ,2 ]
Guenther, H. [1 ,2 ]
Ubbelohde, U. [1 ,2 ]
Stroszczynski, C. [1 ,2 ]
Ehninger, G. [1 ,2 ]
Folprecht, G. [1 ,2 ]
机构：
[1] W German Canc Ctr, Essen, Germany
[2] Univ Hosp Carl Gustav Carus, Dresden, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15025
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial.
    Schalhorn, A
    Ludwig, FW
    Quietzsch, D
    Maubach, PA
    Schlimok, G
    Lambertz, H
    Weigang-Koehler, K
    Schulze, M
    Schlag, R
    Grundeis, M
    Heinemann, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 250S - 250S
  • [22] A triplet combination with oxaliplatin/capecitabine/irinotecan (XELOXIRI) plus cetuximab (Cmab) as a first-line therapy in wild-type KRAS, metastatic colorectal cancer: a dose escalating study
    Sato, Y.
    Ohnuma, H.
    Hirakawa, M.
    Kikuch, S.
    Takahashi, M.
    Okamoto, T.
    Tsuji, Y.
    Okita, K.
    Furuhata, T.
    Takemasa, I.
    Kato, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Oxaliplatin, 5-fluorouracil (FU) & folinic acid (FA) first-line combination therapy in colorectal cancer:: Results of a phase III trial.
    Seymour, MT
    Cassidy, J
    Wilson, C
    Papamichael, D
    Homerin, M
    Figer, A
    de Gramont, A
    BRITISH JOURNAL OF CANCER, 1998, 78 : 21 - 21
  • [24] Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting:: a phase II study
    Cervantes, A.
    Casac, E.
    Van Cutsem, E.
    Sastre, J.
    Andre, T.
    Humblet, Y.
    Van Laethem, J.
    Zubel, A.
    Gascon, N.
    de Gramont, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 181 - 182
  • [25] Cetuximab/irinotecan/5-FU +/-oxaliplatin or FOLFOXIRI plus /- bevacizumab in patients with colorectal cancer and nonresectable liver metastases (AIO CELIM2-study).
    Folprecht, Gunnar
    Mende, Marika
    Liersch, Torsten
    Bechstein, Wolf Otto
    Kohne, Claus-Henning
    Stein, Alexander
    Kunzmann, Volker
    Ghadimi, Michael
    Neumann, Ulf Peter
    Nilsson, Sven
    Koenig, Alexander
    Pession, Ursula
    Troja, Achim
    Glados, Manfred
    Kleiss, Mathias
    Ubbelohde, Ulrike
    Weitz, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR)
    Van Cutsem, Eric J. D.
    Tabemero, J.
    Diaz-Rubio, E.
    Chirivella, I.
    Andre, T.
    Humblet, Y.
    Van Laethem, J-L
    Kisker, O.
    Farres, J.
    de Gramont, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 91 - 91
  • [27] Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid vs high dose 24h 5-FU infusion/folinic acid (FA) plus oxaliplatin(OXA) in metastatic colorectal cancer (MCRC).
    Hospers, G
    Schaapveld, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 254S - 254S
  • [28] DOSE INTENSITY AND TOLERANCE IMPROVEMENT OF CETUXIMAB, IRINOTECAN, 5-FU AND FOLINIC ACID IN PATIENTS WITH METASTATIC CRC; A PHARMACOKINETIC AND PHARMACOGENETIC APPROACH
    Gamelin, E.
    Metges, J.
    Adenis, A.
    Raoul, J.
    Lam, Y.
    Lecomte, T.
    Faroux, R.
    Luet, D.
    Masliah, C.
    Berger, V.
    ANNALS OF ONCOLOGY, 2008, 19 : 131 - 131
  • [29] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Okagawa, Yutaka
    Murase, Kazuyuki
    Takada, Kohichi
    Kawano, Yutaka
    Iyama, Satoshi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Mizuguchi, Toru
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 587 - 594
  • [30] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Yasushi Sato
    Hiroyuki Ohnuma
    Masahiro Hirakawa
    Minoru Takahashi
    Takahiro Osuga
    Yutaka Okagawa
    Kazuyuki Murase
    Kohichi Takada
    Yutaka Kawano
    Satoshi Iyama
    Tsuyoshi Hayashi
    Tsutomu Sato
    Koji Miyanishi
    Rishu Takimoto
    Masayoshi Kobune
    Kenji Okita
    Toru Mizuguchi
    Tomohisa Furuhata
    Koichi Hirata
    Junji Kato
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 587 - 594
12345